

CAR T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations

Authors

Angela Hwang,¹ Amy A. Kirkwood,^{2,3} Prudence Hardefeldt,⁴ Mathew Amrith,⁵ Maeve O'Reilly,¹ Andrea Kuhn,⁴ Michael Northend,¹ Paul Maciocia,^{1,2} Sridhar Chaganti,⁵ Kate Cwynarski,¹ Robin Sanderson⁴ and Claire Roddie^{1,2}

¹Department of Hematology, University College London Hospitals, London; ²UCL Cancer Institute, University College London, London; ³Cancer Research UK & UCL Cancer Trial Center, UCL Cancer Institute, University College London, London; ⁴Department of Hematology, King's College Hospital, London and ⁵Department of Hematology, Queen Elizabeth Hospital, Birmingham, UK

Correspondence:

C. RODDIE - c.rodzie@ucl.ac.uk

<https://doi.org/10.3324/haematol.2025.300151>

Received: November 4, 2025.

Accepted: March 25, 2026.

Early view: April 2, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



TITLE:

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

SUPPLEMENTARY TABLES:***Supplementary Table S1: HIV and large B-cell lymphoma diagnostic details***

	All patients N=11	Infused N=8
Age at HIV diagnosis, median (IQR) <i>Range</i>	39.5 (31-46) 0-72	38 (31-43) 0-46
Interval between HIV and LBCL diagnosis (years), median (IQR) <i>Range</i>	16 (5-23) 0-31	19 (12-29) 0-31
Histological subtype, N (%) DLBCL	11 (100)	8 (100)
CD4 ⁺ count at LBCL diagnosis, median (IQR) <i>Range</i>	65 (undetectable-129) undetectable-182	40 (undetectable-110) undetectable-148
HIV viral load at LBCL diagnosis, median (IQR) <i>Range</i>	<40 (undetectable-55000) undetectable-6,840,000	<40 (undetectable-1,288,250) undetectable-6,840,000
1 st line therapy, N (%) R-CHOP R-Pola-CHP R-GCVP	7 (64) 2 (18) 2 (18)	4 (50) 2 (25) 2 (25)
Response to 1 st line therapy, N (%) CR PR PD	1 (9) 2 (18) 8 (73)	0 2 (25) 6 (75)
Number of lines prior therapy, median (IQR) <i>Range</i>	2 (1-3) 1-3	2 (1-3) 1-3

Key: IQR – interquartile range; LBCL – Large B Cell Lymphoma; R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-Pola-CHP – rituximab, polatuzumab vedotin, cyclophosphamide, vincristine, prednisolone; R-GCVP – rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone; CR – complete response; PR – partial response; PD – progressive disease

Supplementary Table S2: Comparison between the HIV-positive Large B-cell Lymphoma CAR-T datasets

	UK	DESCAR-T¹	AMC and CIBMTR²
Median age	53.5	55	56
Range	32-62	35-75	29-69
Total infused, N	8	24	35
Male sex, %	75	71	88.6
Histological subtype, %			
LBCL	100	84	91
Follicular		8	6
Other		4 (grey-zone)	3 (mantle)
CAR-T product, %			
Axi-cel	100	100	97
Brexu-cel			3
Bridging therapy, %			
Yes	100	63	62.9
Type	Systemic: 63 RT: 25 Combination: 13	Chemotherapy-based: 37	N/A
Bridging response, N (%)	CR/PR: 2 (25) PD: 6 (75)	Responder: N/A No response: 11 (73)	N/A
Stage, N (%)			
I/II	2 (25)	N/A	N/A
III/IV	6 (75)	18 (90)	
Missing		4	
Elevated LDH pre-LD or pre-CAR-T infusion, N (%)			
Yes	4 (66)	15 (63)	N/A
Missing	2		
Median prior lines treatment	2	3	N/A
Range	1-3	1-4	
HIV VL pre-LD or pre-CAR-T infusion	Not detectable: 8/8 (100%)	Not detectable: 11/24 (46%) Not reported: 13/24	Median VL: 20 copies/ml (0-10x10 ⁶) >400 copies/ml: 11.4%
Response rate	M3 ORR: 25% CR: 25%	M3 ORR: 50% CR: 42%	M6 ORR: 42.6% CR: 34.6%
Survival outcomes	Median PFS: 0.9 months (IQR: 0.8-1.7) Median OS: 10.8 months (IQR: 1.7-11.8)	1 year PFS: 40% (95% CI, 18-61) 1 year OS: 55% (95% CI, 28-75)	1/2 year PFS: 36.1/28.3% 1/2 year OS: 45.7/ 37.3%

Key: UK – United Kingdom; NCCP – National CAR-T cell panel; DESCAR-T – Dispositif d'Enregistrement et Suivi des patients traités par CAR-T cells; AMC – AIDS Malignancy Consortium; CIBMTR – Center for International Blood & Marrow Transplant Research; LBCL – Large B-cell Lymphoma; RT – radiotherapy; CR – complete response; PR – partial response; PD – progressive disease; LDH – Lactate dehydrogenase; LD – lymphodepletion; VL – viral load; M3 – month 3; ORR

– overall response rate; M6 – month 6; PFS – progression free survival; IQR – interquartile range; OS – overall survival

REFERENCES

1. Clerico M, André A, Sesques P, et al. CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry. *Blood* 2024;1443124.
2. Barta S, Noy A, Ahn KW, et al. CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC). *Blood* 2025;146955.